PainReform (NASDAQ:PRFX) Receives Hold Rating from Maxim Group

PainReform (NASDAQ:PRFX)‘s stock had its “hold” rating reaffirmed by equities researchers at Maxim Group in a research note issued on Thursday, Benzinga reports.

PainReform Stock Performance

Shares of NASDAQ:PRFX traded down $0.04 on Thursday, hitting $0.70. The stock had a trading volume of 7,151 shares, compared to its average volume of 166,450. The firm’s 50 day moving average price is $0.56 and its 200-day moving average price is $0.63. PainReform has a twelve month low of $0.53 and a twelve month high of $20.16. The company has a market capitalization of $406,058.00, a price-to-earnings ratio of -0.02 and a beta of 0.54.

PainReform (NASDAQ:PRFX) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.40) EPS for the quarter.

Institutional Investors Weigh In On PainReform

A hedge fund recently raised its stake in PainReform stock. Armistice Capital LLC boosted its holdings in PainReform Ltd. (NASDAQ:PRFX) by 76.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 276,000 shares of the company’s stock after acquiring an additional 120,000 shares during the period. Armistice Capital LLC owned 13.60% of PainReform worth $132,000 as of its most recent filing with the Securities and Exchange Commission. 37.28% of the stock is currently owned by institutional investors.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.